Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Enolase 1 pseudogene 2 (ENO1P2) is a genomic DNA sequence that resembles the functional enolase 1 (ENO1) gene but is categorically a pseudogene, meaning it does not encode an active enzyme or protein. Several ENO1 pseudogenes exist in the human genome, and while ENO1 has important roles in glycolysis and is implicated in cancer biology, its pseudogenes, including ENO1P2, are not characterized as having direct biological functions or clinical significance[2][4]. They may be involved in genomic structural variation or regulation but are not regarded as therapeutic targets or biomarkers. ENO1P2 is a pseudogene derived from the enolase 1 gene, not a druggable target, and is not involved in known disease mechanisms or therapy; its relevance lies only in genetic annotation rather than biomedical targeting. If the intent was to refer to the functional enolase 1 (ENO1), considerably more roles in metabolism, cancer, and as a biomarker would apply[1][2][4][6][8].
None (no drug action mechanism, as it is not a protein or functional gene product)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Enolase 1 pseudogene 2 (ENO1P2).